ENDRA Life Sciences

NDRA72

$5.09arrow_drop_down4.17%-$0.21

NDRA72

$5.09

arrow_drop_down4.17%-$0.21

Performance History

Key Stats
Open	$5.25
Prev. Close	$5.27
EPS	-2,966.92
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$2.63M
PE Ratio	-

	LOW	HIGH
Day Range	4.93	5.72
52 Week Range	0.19	139.50

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-2,966.92

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About ENDRA Life Sciences (NDRA)

ENDRA Life Sciences Inc (NDRA) is a medical technology company that focuses on developing innovative solutions for the assessment and management of liver disease. The company's proprietary Endra UltraSound System (EU5) is designed to provide non-invasive, quantitative measurement of hepatic fat, liver function, and other related parameters. With its cutting-edge technology, ENDRA aims to revolutionize the way liver disease is diagnosed and monitored, ultimately improving patient outcomes and reducing healthcare costs.

The stock price history of ENDRA Life Sciences Inc (NDRA) has shown significant volatility in recent years. The stock reached its all-time high of $8.75 per share in January 2018 but has since experienced a significant decline. As of the latest trading session, the stock is trading at around $1.25 per share, reflecting the challenging market conditions for the company.

Websitecall_made

Sector: Healthcare
Industry: Diagnostics & Research
CEO: Mr. Francois Michelon
Headquarters: Ann Arbor
Employees: 21
Exchange: NASDAQ

Keep an eye on ENDRA Life Sciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of ENDRA Life Sciences (NDRA)?

ENDRA Life Sciences (NDRA) has a market capitalization of $2.64M. The average daily trading volume is 5.21, indicating the stock's liquidity and investor engagement.

help

What is ENDRA Life Sciences 's (NDRA) price per share?

The current price per share for ENDRA Life Sciences (NDRA) is $5.09. The stock has seen a price change of -$0.22 recently, indicating a -4.17% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for ENDRA Life Sciences (NDRA)?

For ENDRA Life Sciences (NDRA), the 52-week high is $139.5, which is 2.64K% from the current price. The 52-week low is $0.19, the current price is 2.58K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is ENDRA Life Sciences (NDRA) a growth stock?

ENDRA Life Sciences (NDRA) has shown an average price growth of -4.13% over the past three years. It has received a score of 92 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ENDRA Life Sciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ENDRA Life Sciences (NDRA) stock price performance year to date (YTD)?

As of the latest data, ENDRA Life Sciences (NDRA) has a year-to-date price change of -99.82%. Over the past month, the stock has experienced a price change of -65.22%. Over the last three months, the change has been -67.33%. Over the past six months, the figure is -99.08%. Looking at a longer horizon, the five-year price change stands at -99.98%.

help

Is ENDRA Life Sciences (NDRA) a profitable company?

ENDRA Life Sciences (NDRA) has a net income of -$10.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$10.52M. Furthermore, the EBITDA is -$9.52M.